PuraStat shows its efficacy in achieving endoscopic haemostasis in postoperative anastomotic ulcers

A new interesting case report highlights the efficacy of PuraStat for achieving endoscopic...

3-D Matrix Summer Update

3-D Matrix would like to wish you all a wonderful summer and take this opportunity to remind you...

3-D Matrix strengthens its relationship with its distribution partners.

During 3-D Matrix's quarterly European sales meeting, held in Barcelona from the 22nd to the 24th...

Notice regarding the Conclusion of an Agreement Concerning Manufacturing License with FUSO Pharmaceutical Industries, Ltd.

3-D Matrix, Ltd. (headquarters: Chiyoda-ku, Tokyo; President and Representative Director: Jun...

3-D Matrix keeps aiming in the ENT and Plastic Surgery medical areas with PuraBond

The 3-D Matrix agenda keeps being filled with a selection of events, including those dedicated to...

First clinical data demonstrating PuraStat’s safety and efficacy for haemostasis in thyroidectomy and parathyroidectomy. A case series of 353 patients.

Cervical endocrine surgeries such as thyroidectomy and parathyroidectomy can carry the risk of...

US Notice Regarding Marketing Approval for Radiation Proctitis Wound Healing Material

We are pleased to announce that the 510K submitted to the United States Food and Drug...

Controlled Trial to Evaluate the Efficacy of PuraStat in Reducing  Delayed Bleeding (in high-risk patients) After Colonic Endoscopic Submucosal Dissection Has Started in France.

The new clinical trial “Multicentre Randomised Controlled Trial (RCT) to assess the efficacy of a...

First Human Clinical Investigation of the Next Generation Self-Assembling Haemostat [in progress]

The clinical investigation ‘First-in-Human Trial of the Safety and Performance of NU-MAX® as a...

Notice regarding the submission for new manufacturing process for haemostatic products in Europe

We are pleased to announce that on the 13th January 2022, our European subsidiary 3-D Matrix Europe...